Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon May 28, 2013 3:59pm

268 Views

Post# 21451557

RE: RE: RE: RE: RE: RE: RE: Any Word on the Meetin

Results IN 5 weeks, as jonzobot posted, or results WITHIN 5 weeks, as Albertaclipper posted? I know DM has said end of June several times, but I still have my fantasy scenario the Nissen might present these results at the EAS meeting on June 4th. Fat chance, I know. Any clarification on this would be much appreciated.

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns